T. Rowe Price Associates’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-27,983
| Closed | -$1.05M | – | 2989 |
|
|
2021
Q1 | $1.05M | Sell |
27,983
-1,669,676
| -98% | -$41.6M | ﹤0.01% | 2023 |
|
|
2020
Q4 | $28.9M | Buy |
+1,697,659
| New | +$21.3M | ﹤0.01% | 1121 |
|
|
2020
Q2 | – | Sell |
-37,397
| Closed | -$85K | – | 2561 |
|
|
2020
Q1 | $85K | Buy |
37,397
+17,600
| +89% | +$74.7K | ﹤0.01% | 2429 |
|
|
2019
Q4 | $91K | Buy |
19,797
+1,658
| +9% | +$6.57K | ﹤0.01% | 2466 |
|
|
2019
Q3 | $70K | Buy |
18,139
+136
| +0.8% | +$746 | ﹤0.01% | 2476 |
|
|
2019
Q2 | $109K | Sell |
18,003
-1,004,444
| -98% | -$9.6M | ﹤0.01% | 2468 |
|
|
2019
Q1 | $13.7M | Sell |
1,022,447
-10,871
| -1% | -$124K | ﹤0.01% | 1267 |
|
|
2018
Q4 | $9.61M | Sell |
1,033,318
-7,936
| -0.8% | -$94.4K | ﹤0.01% | 1314 |
|
|
2018
Q3 | $14.5M | Buy |
1,041,254
+3,313
| +0.3% | +$49.3K | ﹤0.01% | 1309 |
|
|
2018
Q2 | $16.4M | Sell |
1,037,941
-96,124
| -8% | -$1.68M | ﹤0.01% | 1264 |
|
|
2018
Q1 | $19.5M | Buy |
1,134,065
+852,858
| +303% | +$16.6M | ﹤0.01% | 1193 |
|
|
2017
Q4 | $6.16M | Buy |
+281,207
| New | +$9.04M | ﹤0.01% | 1410 |
|
|
2016
Q3 | – | Sell |
-39,045
| Closed | -$1.61M | – | 2575 |
|
|
2016
Q2 | $1.61M | Buy |
+39,045
| New | +$1.7M | ﹤0.01% | 1577 |
|
|
2016
Q1 | – | Sell |
-318,580
| Closed | -$13.2M | – | 2537 |
|
|
2015
Q4 | $13.2M | Sell |
318,580
-291,040
| -48% | -$9.76M | ﹤0.01% | 1217 |
|
|
2015
Q3 | $9.38M | Sell |
609,620
-11,190
| -2% | -$240K | ﹤0.01% | 1320 |
|
|
2015
Q2 | $15.4M | Sell |
620,810
-1,800
| -0.3% | -$40.1K | ﹤0.01% | 1222 |
|
|
2015
Q1 | $14.2M | Buy |
622,610
+205,000
| +49% | +$5.17M | ﹤0.01% | 1232 |
|
|
2014
Q4 | $11.3M | Buy |
417,610
+166,795
| +67% | +$2.87M | ﹤0.01% | 1292 |
|
|
2014
Q3 | $2.94M | Buy |
+250,815
| New | +$3.16M | ﹤0.01% | 1527 |
|
T. Rowe Price Associates's FPRX Position: Q2 2021 in Review
T. Rowe Price Associates sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 27,983 shares — an estimated $1.05M sold.
T. Rowe Price Associates first reported a position in FPRX in Q3 2014 and held it in 19 quarters. The position peaked at $28.9M in Q4 2020. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- T. Rowe Price Associates reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- T. Rowe Price Associates sold 27,983 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $1.05M.
- T. Rowe Price Associates first reported a position in Five Prime Therapeutics, Inc. in Q3 2014 and held it in 19 quarters.
- T. Rowe Price Associates's Five Prime Therapeutics, Inc. position peaked at $28.9M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on T. Rowe Price Associates's 13F filing for Q2 2021, filed 16 Aug 2021.